Document is current
Any future updates will be listed below
-
Authors
Smith, Ellesha A. http://orcid.org/0000-0002-4241-7205
Cooper, Nicola J.
Sutton, Alex J.
Abrams, Keith R.
Hubbard, Stephanie J.
-
Funding
Funding for this research was provided by:
National Institute for Health Research (DRF-2018-11-ST2-033)
- License Information
-
More Information
Article History
Received: 22 September 2020
Accepted: 4 January 2021
First Online: 3 February 2021
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: KA is supported by Health Data Research (HDR) UK, the UK National Institute for Health Research (NIHR) Applied Research Collaboration East Midlands (ARC EM), and as a NIHR Senior Investigator Emeritus (NF-SI-0512-10159). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. KA has served as a paid consultant, providing unrelated methodological advice, to; Abbvie, Amaris, Allergan, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Meyers Squibb, Creativ-Ceutical, GSK, ICON/Oxford Outcomes, Ipsen, Janssen, Eli Lilly, Merck, NICE, Novartis, NovoNordisk, Pfizer, PRMA, Roche and Takeda, and has received research funding from Association of the British Pharmaceutical Industry (ABPI), European Federation of Pharmaceutical Industries & Associations (EFPIA), Pfizer, Sanofi and Swiss Precision Diagnostics. He is a Partner and Director of Visible Analytics Limited, a healthcare consultancy company.
